Invega (Paliperidone)

Paliperidone is an atypical antipsychotic used in the management of psychotic disorders. It works within the dopamine and serotonin pathways to reduce symptoms.

• Schizophrenia: helps control hallucinations, delusions and thought disorder.
• Schizoaffective disorder: alleviates both mood and psychotic symptoms.
• Maintenance therapy: supports long‑term stability after acute symptom control.

• Paliperidone acts as an antagonist at dopamine D2 receptors and serotonin 5‑HT2A receptors, reducing dopaminergic neurotransmission and modulating serotonergic activity. This dual receptor blockade helps normalize the neurochemical imbalances associated with psychotic and mood symptoms, contributing to symptom improvement and relapse prevention.

Paliperidone may cause a range of adverse reactions, from mild to severe. Awareness of these effects supports safe monitoring.

Common Side Effects

• Headache: mild to moderate intensity.
• Insomnia: difficulty initiating or maintaining sleep.
• Nausea: occasional gastrointestinal upset.
• Weight gain: modest increase in body weight.
• Restlessness (akathisia): feeling of inner tension.
• Dry mouth: reduced salivation.

Serious or Rare Side Effects

• Neuroleptic malignant syndrome: life‑threatening reaction with fever and rigidity.
• Tardive dyskinesia: persistent involuntary movements.
• Seizures: increased risk in susceptible individuals.
• Orthostatic hypotension: sudden drop in blood pressure upon standing.
• Hyperglycemia: elevated blood glucose levels.
• Elevated prolactin: menstrual disturbances or galactorrhea.

Before initiating therapy, clinicians should evaluate patient history and monitor for specific risks.

• Cardiovascular assessment: check for QT prolongation or arrhythmias.
• Metabolic monitoring: regularly assess weight, glucose and lipid levels.
• Psychiatric evaluation: watch for worsening depression or suicidal thoughts.
• Renal function: adjust if severe impairment is present.
• Pregnancy and lactation: discuss potential risks with the patient.
• Store at ambient temperature: keep tablets in original container, protect from moisture and light.

Paliperidone can interact with several drug classes; awareness helps avoid adverse events.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin): may reduce paliperidone exposure.
• QT‑prolonging agents (e.g., certain antiarrhythmics): increase risk of cardiac arrhythmias.
• CNS depressants (e.g., benzodiazepines): may enhance sedation.

Moderate Interactions (Monitor Closely)

• Antihypertensives: additive effect on blood pressure lowering.
• Anticholinergic drugs: may exacerbate dry mouth and constipation.
• Lithium: potential for increased neurotoxicity.
• NSAIDs: may increase risk of gastrointestinal bleeding.